NR3C2 and heart failure: A previous meta-analysis studied the effects of beta-blocker, ACE inhibitors, aldosterone receptor blockers, and mineralocorticoid receptor antagonists on all-cause mortality, cardiovascular mortality, heart failure hospitalization, exercise tolerance, quality of life and biomarkers in HFpEF patients, which showed no effect of any single drug on HFpEF compared with placebo, but the reduction of all-cause mortality and cardiovascular mortality with beta-blocker (Zheng et al., 2018).